menu

Joint Research Management Office

About us menu

JRMO performance

Clinical research overview - June 2019

Financial headlines

  • Estimated Financial Turnover for JRMO managed clinical research (FY 2018-19):
    • Barts Health - £24m
    • Queen Mary School of Medicine and Dentistry - £71m
  • Of this figure, estimated Commercial clinical research Turnover (FY 2018-19):
    • Barts Health - £7m
    • Queen Mary School of Medicine and Dentistry - £13m

Research portfolio

  • Sponsored Studies (all types), June 2019:
    • Barts Health – 28
    • Queen Mary School of Medicine and Dentistry – 37
  • Sponsored Studies actively recruiting, June 2019: All the above.
  • NIHR portfolio studies Sponsored, June 2019:
    • Barts Health – 9
    • Queen Mary School of Medicine and Dentistry – 15
  • Hosted NIHR portfolio studies (Barts Health only), June 2019 - 241
  • Hosted CTIMPs (Barts Health only), June 2019 - 134
  • Hosted Commercially Sponsored studies (Barts Health only), June 2019 - 120
  • Patients recruited to NIHR portfolio studies at Barts Health at end FY 2017-18 – 17,199
  • European Union Clinical Trials Register (EU-CTR) of clinical trials registered within 1 year of completion, May 2019:
    • Barts Health as Sponsor– 88.2%
    • Queen Mary as Sponsor– 100%
    • Queen Mary/ Barts Health joint Sponsor– 100%

 JRMO activity

  • JRMO grant applications supported in Q4, 2018-19:
    • Barts Health – 6 (value £1m)
    • Queen Mary School of Medicine and Dentistry – 250 (value £100m)
  • JRMO contracts reviewed in Q4, 2018-19:
    • Barts Health – 162
    • Queen Mary School of Medicine and Dentistry - 383
  • JRMO invoices issued:
    • Barts Health – 549 (value £12m) (Q3 17/18)
    • Queen Mary School of Medicine and Dentistry – 709 (value £14m) (Q4 18/18) 

Historical Queen Mary statistical data

This data, previously located on the old JRMO intranet site, can be supplied on request by John Driscoll in the JRMO: j.p.driscoll@qmul.ac.uk 

 

Return to top